Summary:
- The article discusses the decision by the U.S. Agency for International Development (USAID) to abandon clinical trials in developing countries, which is described as "indiscriminate, cruel, and wasteful."
- It argues that this move will have significant negative consequences, as these trials are crucial for developing new treatments and vaccines for diseases that disproportionately affect populations in low- and middle-income countries.
- The article emphasizes the importance of continuing these clinical trials, as they not only benefit the local communities but also contribute to global health research and the development of essential medical interventions.